📣 VC round data is live. Check it out!

Oryzon Genomics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oryzon Genomics and similar public comparables like Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics and more.

Oryzon Genomics Overview

About Oryzon Genomics

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.


Founded

2000

HQ

Spain

Employees

40

Website

oryzon.com

Financials (LTM)

Revenue: $3M
EBITDA: ($10M)

EV

$253M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Oryzon Genomics Financials

Oryzon Genomics reported last 12-month revenue of $3M and negative EBITDA of ($10M).

In the same LTM period, Oryzon Genomics generated $3M in gross profit, ($10M) in EBITDA losses, and had net loss of ($7M).

Revenue (LTM)


Oryzon Genomics P&L

In the most recent fiscal year, Oryzon Genomics reported revenue of - and EBITDA of ($6M).

Oryzon Genomics is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.

See analyst estimates for Oryzon Genomics
LTMLast FY202320242025202620272028
Revenue$3M----
Gross Profit$3M$13M$15M$7M$13M
Gross Margin89%----
EBITDA($10M)($6M)($4M)($4M)($6M)
EBITDA Margin(308%)----
EBIT Margin(386%)----
Net Profit($7M)($3M)($4M)($4M)($3M)
Net Margin(226%)----

Financial data powered by Morningstar, Inc.

Oryzon Genomics Stock Performance

Oryzon Genomics has current market cap of $278M, and enterprise value of $253M.

Market Cap Evolution


Oryzon Genomics' stock price is $3.58.

Oryzon Genomics share price decreased by 2.3% in the last 30 days, and increased by 16.7% in the last year.

Oryzon Genomics has an EPS (earnings per share) of $-0.04.

See more trading valuation data for Oryzon Genomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$253M$278M0.3%-2.3%9.9%16.7%$-0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Oryzon Genomics Valuation Multiples

Oryzon Genomics trades at 78.6x EV/Revenue multiple, and (25.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Oryzon Genomics

EV / Revenue (LTM)


Oryzon Genomics Financial Valuation Multiples

As of June 3, 2026, Oryzon Genomics has market cap of $278M and EV of $253M.

Oryzon Genomics has a P/E ratio of (38.2x).

LTMLast FY202320242025202620272028
EV/Revenue78.6x----
EV/EBITDA(25.5x)(44.4x)(56.5x)(58.0x)(44.4x)
EV/EBIT(20.4x)(37.8x)(50.4x)(55.0x)(37.8x)
EV/Gross Profit88.4x20.2x16.4x34.5x20.2x
P/E(38.2x)(90.7x)(74.9x)(72.8x)(90.7x)
EV/FCF(21.0x)(25.6x)(15.2x)(18.2x)(16.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Oryzon Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Oryzon Genomics Margins & Growth Rates

Oryzon Genomics grew EBITDA by 100% in the last fiscal year.

See estimated margins and future growth rates for Oryzon Genomics

Oryzon Genomics Margins

2026202720282029
Gross Margin95%
EBITDA Margin(149%)
EBIT Margin(186%)
Net Margin(162%)
FCF Margin(197%)

Oryzon Genomics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Gross Profit Growth(42%)(52%)70%(42%)
EBITDA Growth100%(3%)31%100%
EBIT Growth112%(8%)46%112%
Net Profit Growth303%3%(20%)303%
FCF Growth52%(16%)13%(4%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Oryzon Genomics Operational KPIs

Oryzon Genomics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Oryzon Genomics
LTMLast FY202620272028
Rule of 40(13%)-
Bessemer Rule of X429%-
Revenue per Employee-$0.0M
Opex per Employee-$0.5M
G&A Expenses to Revenue181%-
R&D Expenses to Revenue510%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Oryzon Genomics Competitors

Oryzon Genomics competitors include Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio and Organogenesis.

Most Oryzon Genomics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Immuneering--(2.1x)-
Panacea Biotec3.9x-79.5x-
Prelude Therapeutics17.8x11.3x(2.1x)(2.0x)
IMBiologics-27.6x--
Santhera Pharma3.2x2.9x(7.8x)(11.9x)
Zentalis Pharma--(0.7x)(0.7x)
Eledon Pharmaceuticals--(2.0x)-
Surrozen48.5x35.8x(4.1x)-

This data is available for Pro users. Sign up to see all Oryzon Genomics competitors and their valuation data.

Start Free Trial

Oryzon Genomics VC Funding History

Before going public, Oryzon Genomics raised $19M in total equity funding, across 1 round.

Last private valuation of Oryzon Genomics was $110M, after raising $19M in October 2015.


Oryzon Genomics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-15Series C-$19M$110MOryzon Genomics S.A. is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, focused on discovering and developing epigenetic therapies for oncology and neurodegenerative diseases. The company's lead asset ORY-1001 is being developed for acute myeloid leukemia under a global strategic collaboration with Roche that includes potential development, commercial, and sales milestones exceeding $500 million, in addition to an upfront payment and near-term milestones totaling $21 million. In October 2015, Oryzon raised €16.5 million through a private placement at €3.39 per share, resulting in a post-transaction valuation of $110 million. The round was led by Bank Solventis AV, with new shareholders including the CEO of Active Motif and a founder of Invitrogen, gaining 17% of outstanding shares. The company used proceeds to advance development of multiple therapeutic programs, including its ORY-2001 program for neurodegenerative diseases, and successfully listed on the Madrid Stock Exchange in December 2015 under ticker ORY.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Oryzon Genomics

When was Oryzon Genomics founded?Oryzon Genomics was founded in 2000.
Where is Oryzon Genomics headquartered?Oryzon Genomics is headquartered in Spain.
How many employees does Oryzon Genomics have?As of today, Oryzon Genomics has over 40 employees.
Is Oryzon Genomics publicly listed?Yes, Oryzon Genomics is a public company listed on Bolsa de Madrid.
What is the stock symbol of Oryzon Genomics?Oryzon Genomics trades under ORY ticker.
When did Oryzon Genomics go public?Oryzon Genomics went public in 2015.
Who are competitors of Oryzon Genomics?Oryzon Genomics main competitors include Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio, Organogenesis.
What is the current market cap of Oryzon Genomics?Oryzon Genomics' current market cap is $278M.
What is the current revenue of Oryzon Genomics?Oryzon Genomics' last 12 months revenue is $3M.
What is the current revenue growth of Oryzon Genomics?Oryzon Genomics revenue growth (NTM/LTM) is 295%.
What is the current EV/Revenue multiple of Oryzon Genomics?Current revenue multiple of Oryzon Genomics is 78.6x.
Is Oryzon Genomics profitable?No, Oryzon Genomics is not profitable.
What is the current EBITDA of Oryzon Genomics?Oryzon Genomics has negative EBITDA and is not profitable.
What is Oryzon Genomics' EBITDA margin?Oryzon Genomics' last 12 months EBITDA margin is (308%).
What is the current EV/EBITDA multiple of Oryzon Genomics?Current EBITDA multiple of Oryzon Genomics is (25.5x).
What is the current FCF of Oryzon Genomics?Oryzon Genomics' last 12 months FCF is ($12M).
What is Oryzon Genomics' FCF margin?Oryzon Genomics' last 12 months FCF margin is (374%).
What is the current EV/FCF multiple of Oryzon Genomics?Current FCF multiple of Oryzon Genomics is (21.0x).
How many companies Oryzon Genomics has acquired to date?Oryzon Genomics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Oryzon Genomics has invested to date?Oryzon Genomics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Oryzon Genomics

Lists including Oryzon Genomics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial